CSLLY News and Press, CSL Ltd ADR From 08/02/23

2023-08-02 06:46:35 ET More on market strategy My Current View Of The S&P 500 Index: August 2023 Edition (Technical Analysis) Avi Gilburt Warns Of Potential Banking Crisis; Charts Indicate Major Disruptions Morgan Stanley bear Wilson sees a 2019-like rally this y...

2023-07-27 09:40:36 ET Summary The news on Starpharma share price is challenging as a significant shareholder exits. The news of commercially interesting developments continues to broaden, meaning that substantial share price upside seems likely. Starpharma has a strong board ...

CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season PR Newswire CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 ...

2023-06-21 05:51:01 ET Summary CSL Limited's FY 2024 profit guidance outlined in a recent announcement last week came in below expectations, and this led to a meaningful correction in its share price. The company's earnings guidance for the new fiscal year was negatively affected ...

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B PR Newswire HEMGENIX ® , the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX ...

Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure Canada NewsWire Injectafer ® (ferric carboxymaltose) is now the first and only intravenous (i.v.) iron replacement therapy in the U.S. indicated for improvement i...

2023-05-22 17:38:02 ET Summary uniQure secured FDA approval late last year and EMA approval in Q1 2023 for its AMT-061 Hemophilia B treatment. This paves the way for its commercialization in the US and EU. It also has a healthy R&D pipeline, with its Huntington’s diseas...

2023-05-18 05:33:23 ET U.K.'s National Institute for Clinical Excellence (NICE) in its guidance recommended Cara Therapeutics ( NASDAQ: CARA ) and Vifor Fresenius Medical Care Renal Pharma's Kapruvia for use in the National Health Service (NHS). The drug pricing watchdog recomme...

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus Canada NewsWire Recommendation will enable eligible patients in England , Wales and Northern Ireland to access the first license...

2023-05-15 08:26:38 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) added ~7% pre-market Monday after announcing an agreement to sell a portion of royalty rights expected to receive from Australian drugmaker CSL Limited ( OTCQX:CSLLY ) in relation to the gene therapy Hemgenix...